Often what parents reach for to relieve a child’s pain or fever, a new meta-analysis looks at the efficacy and safety of ibuprofen and acetaminophen.
When a child is in pain or has a fever, most parents will turn to either ibuprofen or acetaminophen to bring relief. A meta-analysis in JAMA Network Open looked at the analgesic and antipyretic qualities of both as well as the safety profiles.1
The researchers ran a systematic search in MEDLINE, Embase, CINAHL, and the Cochrane Central Register of Controlled Trials, as well as the Australian New Zealand Clinical Trials Registry and ClinicalTrials.gov. Any study that looked at children aged younger than 2 years and was comparing acetaminophen to ibuprofen, and reporting antipyretic, analgesic, and/or safety outcomes were considered. Two researchers independently extracted the data and assessed the quality.
There were 19 studies included in the meta-analysis and the studies covered 241,138 participants. The studies came from 7 different countries and included both hospital- and community-based health care settings. When compared with acetaminophen, they found that ibuprofen reduced temperature at less than 4 hours (4 studies with 435 participants; standardized mean difference [SMD], 0.38; 95% CI, 0.08-0.67; P = .01; I2 = 49%; moderate quality evidence) as well as at 4 to 24 hours (5 studies with 879 participants; SMD, 0.24; 95% CI, 0.03-0.45; P = .03; I2 = 57%; moderate-quality evidence).
Continue reading this article on Contemporary Pediatrics.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.